A sight on the current nanoparticle-based gene delivery vectors by Solmaz Dizaj et al.
Dizaj et al. Nanoscale Research Letters 2014, 9:252
http://www.nanoscalereslett.com/content/9/1/252NANO REVIEW Open AccessA sight on the current nanoparticle-based gene
delivery vectors
Solmaz Maleki Dizaj1,2,3†, Samira Jafari1,2,3† and Ahmad Yari Khosroushahi4,5*Abstract
Nowadays, gene delivery for therapeutic objects is considered one of the most promising strategies to cure both
the genetic and acquired diseases of human. The design of efficient gene delivery vectors possessing the high
transfection efficiencies and low cytotoxicity is considered the major challenge for delivering a target gene to
specific tissues or cells. On this base, the investigations on non-viral gene vectors with the ability to overcome
physiological barriers are increasing. Among the non-viral vectors, nanoparticles showed remarkable properties
regarding gene delivery such as the ability to target the specific tissue or cells, protect target gene against nuclease
degradation, improve DNA stability, and increase the transformation efficiency or safety. This review attempts to
represent a current nanoparticle based on its lipid, polymer, hybrid, and inorganic properties. Among them, hybrids,
as efficient vectors, are utilized in gene delivery in terms of materials (synthetic or natural), design, and in vitro/
in vivo transformation efficiency.
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Introduction
Gene therapy is described as the direct transfer of genetic
material to cells or tissues for the treatment of inherited
disorders and acquired diseases. The base of this thera-
peutic method is to introduce a gene encoding a functional
protein altering the expression of an endogenous gene or
possessing the capacity to cure or prevent the progression
of a disease [1-3]. This method was initially performed
in 1990 in the USA for the treatment of adenosine
deaminase-deficient SCID (combined immune deficiency
disease) patients [4]. This therapy is not only used in gen-
etic deficiencies, but also in other complicated diseases,
such as viral infection (human immunodeficiency virus),
autoimmunity (rheumatoid arthritis), cancer, diabetes,
coronary, and artery disease [5]. With the progress of
this technique, gene therapy will become an effective
therapeutic method for neurodegenerative conditions,* Correspondence: Yarikhosroushahia@tbzmed.ac.ir
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in any medium, provided the original work is phemophilia, AIDS, asthma, and the myriad of other
genetic and acquired diseases that affect humanity [2].
By considering the mentioned issues, the choice of a
suitable method for DNA delivery to the targeted cells
beseems very important at the point of receiving appro-
priate genes. Although gene therapy can be carried out
using naked DNA into the target cells, having negative
nature of cellular membrane and negative charge of
large DNA molecules, the nucleic acid-based therapeu-
tics cannot cross cellular membranes by simple passive
diffusion methods. Hence, to facilitate the transfer of
DNA molecules into a cell, the existence of a vector is
necessary [6,7]. Viral and non-viral vectors, two major
types of vectors for gene delivery, are currently being
utilized in clinical trials at similar levels.
In gene delivery, it is relatively common to follow bio-
mimetic approaches. Biological systems include modified
viruses and mildness bacteria. Viral vectors are more ef-
ficient than non-viral vectors for DNA delivery but may
present a significant risk to patients, while non-viral
carriers are inherently safer than viral carriers [8-10].
Furthermore, in contrast to the viral gene delivery sys-
tems, the non-viral carriers are expected to be less
immunogenic, with simple preparation and a possible
versatile surface modification [7]. The non-viral vectorsOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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other inorganic materials where they can also be prepared
from a lipid-polymer or lipid-polymer-inorganic hybrid.
The choice of gene delivery strategies among several
delivery systems depend on some factors including the im-
provement of vectors, kind of expression systems, and
better understanding of molecular biology of target site and
employing of the advances in the identification of new
genes and new targets [11]. Recently, nanotechnology ap-
proaches play an important role in the design novel and
efficient non-viral gene delivery vectors. In this review, we
will focus on introducing lately synthesized nanoparticles as
vectors with gene delivery applications.
Non-viral vectors
In considering the viral gene delivery vector safety concerns
regarding the risk of excessive immune response (adeno-
virus) and insertion mutagenesis (retroviruses), the use of
non-viral vectors can overcome the mentioned safety prob-
lems [12]. Non-viral vectors either consist of natural vectors
(plasmid DNA or small nucleic acids, antisense oligonucle-
otides, small interfering RNAs) or synthetic vectors
(liposomes, cationic polymers) [11]. Naked DNA, usu-
ally in plasmid form, is the simplest form of non-viral
transferring of a gene into a target cell [13-16]. Because of
low transferring efficiency of a bare plasmid, several phys-
ical (electroporation, ultrasound, gas-filled micro-bubbles)
and chemical (liposomes) approaches have been exploited
to enhance their transformation efficiency [17].Figure 1 Internalization of non-viral vectors into cell and passage toIn another type of classification, non-viral delivery
vectors can be categorized as organic (lipid complexes,
conjugated polymers, cationic polymers, etc.) and inorganic
(magnetic nanoparticles, quantum dots, carbon nanotubes,
gold nanoparticles, etc.) systems [18].
Among the materials used to design non-viral vectors,
attention has recently increased on the natural biomate-
rials due to their unique properties such as biodegrad-
ability, biocompatibility, and controlled release.
The delivery carriers necessitate being small enough to
be internalized into the cells and enter the nucleus pass-
ing through the cytoplasm and escaping the endosome/
lysosome process following endocytosis (Figure 1). The
use of nanoparticles in gene delivery can provide both
the targeted and sustained gene delivery by protecting
the gene against nuclease degradation and improving its
stability [19-22].
Nanoparticles in gene delivery
In the field of nanomedicine, nanotechnology methods
focus on formulating therapeutic biocompatible agents
such as nanoparticles, nanocapsules, micellar systems, and
conjugates [22,23]. Nanoparticles are solid and spherical
structures ranging to around 100 nm in size and prepared
from natural or synthetic polymers [24]. To reach the
large-size nucleic acid molecule, the cytoplasm, or even
the nucleus, a suitable carrier system is required to de-
liver genes to cells which enhance cell internalization
and protect the DNA molecule from nuclease enzymaticnucleus through cytoplasm following endocytosis.
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nanoparticles). To achieve the suitable carrier system,
the nanoparticles can be considered as a good candi-
date for therapeutic applications because of several fol-
lowing reasons: (1) They exist in the same size domain
as proteins,(2) they have large surface areas and ability
to bind to a large number of surface functional groups,
and (3) they possess controllable absorption and release
properties and particle size and surface characteristics
[25]. Nanoparticles can also be coated with molecules to
produce a hydrophilic layer at the surface (PEGylation)
to increases their blood circulation half-life. Poloxamer,
poloxamines, and chitosan have also been studied for
surface modifications. The surface modifications are per-
formed for different objectives: (1) the utilized groups can
usually block the electrostatic and hydrophobic interac-
tions thus protect nanoparticles from opsonization and (2)
targeting of tumors or organs accordingly increases select-
ive cellular binding and internalization through receptor-
mediated endocytosis [24].
Nanoparticles exploited in gene delivery were catego-
rized into four major groups in this investigation for
further explanations.
Lipid-based nanoparticles
Cationic liposomes, cationic lipids, cationic solid lipids,
and cationic emulsions are lipid-based structures rou-
tinely utilized for nucleic acid delivery to cells. Cationic
lipids are positive amphiphilic molecules with four main
constituents: (1) the cationic polar head group, which
has the important role in the self-assembly interaction
with DNA, (2) a hydrophobic chain that affects the phys-
ical properties of the lipid bilayer (such as flexibility and
therefore gene transfer efficiency), (3) a spacer between two
mentioned sections that influences the determination of
chemical stability, biodegradability and gene transfection ef-
ficiency, and (4) a backbone (often glycerol-based) domain
as a scaffold. A large number of cationic lipids have previ-
ously been utilized in gene delivery, such as quaternary am-
monium detergents, cationic derivatives of cholesterol and
diacylglycerol, lipid derivatives of polyamines. Dioleylpropyl
trimethylammonium chloride (DOTMA) and dioleoyl tri-
methylammonium propane (DOTAP) are two of the most
popular cationic lipids [20].
A cationic liposome is a liposome composed of a positive
and a helper lipid which can protect DNA from enzymatic
degradation in blood circulation and can interact with the
negatively charged cell membrane to probably facilitate cell
internalization. Compared to viral vectors, liposomes
possess some preferred properties such as safe prepar-
ation, toxicity monitoring, and risk reduction of im-
munological problems by controlling their size using
ultrasonication or extrusion through porous mem-
branes with specific pore sizes.Cationic solid lipid core-shell structures were composed
from high melting point lipids as core and surfactants as
covered shell. These structures have low transformation ef-
ficiency and slight risk of toxicity at high-dose applications
which are considered as promising vectors for systemic
administrations. The solid lipid nanoparticles (SLNs) can
condense DNA into nanometric colloidal particles and able
to transfect mammalian cells under in vitro conditions.
Comparisons between cationic lipids and cationic polymers
illustrated some advantages for SLNs such as (1) a relative
ease of production without requirements for organic sol-
vents, (2) the possibility of large scale production with
qualified production lines, and (3) good storage stabili-
ties together with the possibility of steam sterilization
and lyophilization [20,26,27].
Cationic emulsions were constructed using a hydro-
phobic oil phase covered by the cationic lipid. These cat-
ionic emulsions possess remarkable advantages such as
their nanosized range, biocompatibility, biodegradability,
physical stability, and low toxicity which make them as
favorable carriers for delivering gene to the targeted
cells. Furthermore, easy and low cost productions of cat-
ionic emulsions provide the scaling-up possibility for
emulsion-based systems [20,28].
Polymer-based nanoparticles
Cationic polymers are one of the most significant non-
viral gene delivery systems. These polymers have posi-
tively charged groups in their backbone and can interact
with the negative charge of anionic genetic materials
[29]. Cationic polymers can bind to DNA molecules to
form neutralized, nanometer-sized complexes known as
polyplexes. Polyplexes have some advantages compared
to lipoplexes (complex of lipids-DNA) such as small size,
narrow distribution, higher protection against enzymatic
degradation, more stability, and easy control of the phys-
ical factors. Although, the in vivo efficacy of polymeric
gene delivery is low, using of biomaterials for gene deliv-
ery can reduce many of the safety concerns with viral
gene delivery [25,29].
Due to their unique properties such as biodegradabil-
ity, biocompatibility, and controlled release, natural bio-
polymers and proteins have recently increased attention
in gene delivery. Biopolymers are polymers produced by
living organismsand can be categorized in three groups:
polysaccharides, proteins, and nucleic acids. To fabricate
nanoparticles from these biopolymers, for therapeutic
objects, a variety of materials have been used [25]. Nat-
urally derived proteins such as collagen, elastin, and fi-
bronectin have been used in biomaterial nanoparticle
fabrication. Silk proteins due to their properties such as
slow biodegradability, biocompatibility, self-assembling
property, excellent mechanical property, and control-
lable structure and morphology are promising materials
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component of extracellular matrix, is one of the main
biomaterials in fabrication of gene delivery nanoparticles
due to biocompatibility, low antigenicity, and biodegrad-
ability. Collagen can be formed to hydrogels without the
use of chemical crosslinking, but additional chemical
treatment is necessary for prepared nanoparticles due to
their weak mechanical strengths [23,25]. Collagen is often
chosen as a biomaterial because this protein is abundant in
the animal kingdom and plays a vital role in biological
functions, such as tissue formation, cell attachment, and
proliferation [30]. In addition, proteins such as albumin,
β-casein, and zein are good candidates for fabrication of
nanoparticles due to their non-immunogenicity, non-
toxicity, biodegradability, and biocompatibility [29]. Albu-
min can be considered an ideal material as a delivery carrier
due to its remarkable properties including high binding
capacity, high stability in pH and heat, preferential uptake
in tumor and inflamed tissue, biodegradability, low toxicity,
low immunogenicity, and suitable blood circulation with a
half-time of 19 days [29,31]. Beta casein, the major milk
protein, can self-assemble into micellar structure by inter-
molecular hydrophobic interactions. Therefore, its micellar
structure is a suitable feature for the delivery applications.
Zein is an alcohol-soluble protein existence in corn with
properties such as biocompatibility, low water uptake value,
high thermal resistance, and good mechanical properties.
The main application of zein is in edible coating for foods
and pharmaceuticals. Zein exists as small nanosized glob-
ules and consists of both hydrophobic and hydrophilic
amino acid residues; therefore, it has been applied as a
promising carrier system [23,25,29].
Polysaccharides, long carbohydrate molecules of repeated
monosaccharide units, are another group of biopolymers.
Examples of them consist of chitosan, alginate, heparin,
hyaluronic acid, pullulan, and dextran. The cationic poly-
electrolyte nature of chitosan provides a strong electrostatic
interaction with mucus, negatively charged mucosal
surfaces, and other macromolecules such as DNA [32].
Besides, the presence of primary amine groups in the
structure of chitosan caused this biodegradable, bio-
compatible, and non-toxic biopolymer to be used as an
appealing vector for non-viral genes [33]. It is capable
of forming stable, small (20 to 500 nm) particles with
complex pDNA and its binding efficiency relate to the
molecular weight and the degree of deacetylation [25].
It has better protection against DNase degradation and
higher biocompatibility compare to polymers such as
polyethyleneimine (PEI).
The literatures have shown the physicochemical char-
acteristics of chitosan complexes, such as size, charge,
and complexation efficiency with nucleic acid, are affect-
ing factors in overcoming physiological and cellular bar-
riers to gene delivery [34]. The transfection efficiency ofchitosan started slower but increased over time with
lowering cytotoxity results for in vivo cases.
Polysaccharides and their derivatives are used for bio-
medical applications due to high stability, biocompatibility,
and main of all biodegradability. Three types of celebrated
polysaccharide nanoparticles have been identified by cross-
linking, polyion complex, and self-assembly [25].
Sometimes, the hybrid of protein and polysaccharide
can be used to fabricate nanoparticles for gene delivery.
Albumin-chitosan-DNA-based core-shell nanoparticles
are investigated for gene delivery objectives. The studies
of these nanoparticles showed that they have higher bio-
compatibility and less toxicity compared to poly-L-lysine
(PLL) and PEI. Additionally, their core-shell structure
provides two separate parts for gene delivery [31].
Not only natural protein- or polysaccharide-based
nanoparticles, but also synthetic polymer nanoparticles
have been also paid high attention. Protein-mimicked
polypeptide-based nanoparticles are unique features of
proteins, and today, a number of them have been syn-
thesized. They have properties such as well-defined
composition, monodisperse molecular weight and potential
biocompatibility. These nanoparticles often were fabricated
with a sequence of Val-Pro-Gly-Xaa-Gly by self-assembly of
elastin-like polypeptides (ELP) [25]. Peptide conjugated to
antibody has been used for delivery of siRNA to T cells of
humanized mice to suppress HIV infection [35].
PEI polymers are able to successfully complex DNA
molecules and they also have distinct transfection effi-
ciency in a wide variety of cell types compared to some
other polymer systems described later. PEI derivatives
cross-linked with different acrylates showed high gene
expression in the lung or the spleen in mice. They also
showed only little toxicity in cell culture experiments
[36]. In vivo application of this polymer promises to take
the polymer-based vector to the next level where it can
undergo clinical trials and then could be used for deliv-
ery of therapeutics in humans [37]. PLL is another cat-
ionic polymer, and its efficiency in gene delivery depends
on its molecular weight. In low molecular weight, its
complex with DNA is less soluble and rapidly removed
by the Kupffer cells of the liver. With increasing the mo-
lecular weight, the efficiency of PLL is enhanced, inter-
estingly [38].
Dendrimers are three-dimensional polymers with spher-
ical, highly branched structures. Frequently used dendri-
mers are polyamines, polyamides, or polyesters. Because of
its high transfection efficiency, polyamidoamine (PAMAM)
is the most commonly used. The type of amine groups and
the size of dendrimers have an influence on their transfec-
tion efficiency. The primary amine groups promote DNA
cellular uptake because of their participation in DNA bind-
ing but the buried tertiary amino groups act as a proto-
sponge in endosomes and enhance the release of DNA into
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size and diameter, dendrimers enhance transfection effi-
ciency [39,40]. Recently, nitrogen-core poly(propyl ether
imine) (PETIM) dendrimer DNA complexes have been in-
vestigated and results showed low toxicities and efficient
gene delivery vector properties. Quantitative estimation,
using luciferase assay, showed that the gene transfection
was at least 100 times higher when compared to poly(ethy-
leneimine) branched polymer, having similar number of
cationic sites as the dendrimer [40].
Poly lactic-co-glycolic acid (PLGA)-based nanoparti-
cles have been recognized as a potential vector to deliver
genes. They are used in gene therapy for tumor and
other miRNA-related diseases such as diabetes and
cardiovascular and neurodegenerative diseases. The re-
searches show that PLGA makes an improved safety
profile in comparison with high-molecular weight PEIs
and liposome. Also, it is demonstrated that serum
cannot inhibit the transfection activity of these nano-
particles [41]. PLGA nanoparticles are internalized in
cells through pinocytosis (fluid phase) and also through
clathrin-based endocytosis. These nanoparticles rapidly
escape the endo-lysosomes and enter the cytoplasm
within 10 min of incubation [24]. Nanoparticles consist-
ing of a PLGA core and a chitosan coating (with a posi-
tive charge) can form stable complexes with DNA or
RNA. Researchers showed that in contrast to pure
PLGA particles, the active groups localized on the sur-
face of the carrier caused the fast release [7].
Polyion complex micelles (PICs) are core-shell struc-
tures of polyplex. Initially, Kataoka et al. introduced PIC
micelles using PLL-PEG block copolymer by which PLL
segments and pDNA formed a hydrophobic core by
electrostatic interactions and PEG played a role as a sur-
rounding hydrophilic shell layer [42]. Due to the use of
PEG, PICs have both the higher transfection and the
longer circulation half-life compare to polyplexes. PIC
micelles have some noticeable properties compared to
conventional polyplex and lipoplex systems such as ex-
cellent colloidal stability in protein aqueous media, high
solubility in aqueous media, high tolerance toward nu-
clease degradation, minimal interaction with biological
components, and prolonged blood circulation. Also, in
these systems, with functionalization of PEG group in
the shell, the probability of targeting modification is
enhanced [43]. Thiol-decorated polyion complex micelles
prepared through complexation between PEG-b-poly(2-(N,
N-dimethylamino)ethyl methacrylate) and a 20-mer oligo-
nucleotide have been investigated in this area [44,45].
One main concern about polymeric nanoparticles in
gene delivery is coupling of the interior and exterior
composition of them with polymer backbone and affects
all the functions and biophysical properties of the poly-
mer/DNA particles. One proposed method is coatingpoly(glutamic acid)-based peptide to the exterior com-
position of a core gene delivery particle to change their
function under in vivo conditions [46].
Inorganic nanoparticles
Several inorganic nanoparticles mainly including carbon
nanotubes (CNTs), magnetic nanoparticles, calcium phos-
phate nanoparticles, gold nanoparticles, and quantum dots
(QDs) are routinely utilized as gene delivery carriers. These
nanoparticles possess many advantages in gene delivery.
According to reports, they are not subjected to microbial
attack and show also good storage stability [47].
The use of carbon nanotubes (CNTs) in in vitro applica-
tions has been of interest but their potential for in vivo use
is limited by their toxicity. Due to their nanometer needle
structure, CNTs can easily cross the plasma membrane
using an endocytosis mechanism without inducing cell
death [18]. Single-walled nanotubes have been exploited to
deliver CXCR4 and CD4-specific siRNA to human T cells in
HIV infections [35]. Use of CNTs for biomedical applica-
tions is limited due to their low biocompatibility. Surface
modification or functionalization can increase solubility in
aqueous solutions and biocompatibility [48]. According to
reports, functionalized single-walled nanotubes (SWNTs)
can facilely enter human promyelocytic leukemia (HL60)
and T cells [49]. This ability can be used to deliver bioactive
protein or DNA into mammalian cells.
Fullerenes, especially C60, are water-insoluble allo-
tropes of carbon. Low solubility of fullerenes in the cell
medium can be improved by addition of dimethylforma-
mide (DMF) but it will lead to increased cytoxicity and
consequently reduced cell viability [50]. Recently,
Isobe et. al. (2010) reported that due to their positive
charge and their cationic nature, aminofullerenes have
the capability of transfection with formation fullerene/
DNA complexes [51].
Magnetic nanoparticles have been proven to be effective
in gene delivery particularly in cardiovascular diseases.
These particles are submicron-sized synthetic particles that
respond to magnetic field. In the magnetic drug/gene deliv-
ery system, the gene directly binds to the magnetic particle
or carrier. Magnetic nanoparticles can be dispersed in a
polymer matrix (generally silica, polyvinyl alcohol (PVA) or
dextran) or encapsulated within a polymer or metallic shell.
Targeted gene delivery can be done by attaching different
types of functionalized groups such as carboxyl groups,
amines, biotin, streptavidin, antibodies, and polyethylenei-
mine (particularly in vitro uses) to shell or matrix. The re-
cent research showed that transfection time is significantly
reduced for magnetic nanoparticles in comparison to that
for non-viral agents and that magnetic nanoparticles have
been used to successfully deliver small interfering RNA and
antisense oligonucleotides under in vitro and in vivo condi-
tions [29,52]. Recently, magnetic calcium phosphate nano-
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The DNA-loaded magnetic system in A549 and HepG2
tumor cells indicated that the magnetic nano-formulation
could improve the targeted gene delivery for cancer therapy
with under an external magnetic field.
Metallic nanoparticles, especially GNPs, have the ad-
vantages that they are easy to prepare, have high gene
transfection efficiency, and their surfaces are very amen-
able to chemical modification [54]. Because of low
chemical reactivity and unique stability of gold, this
metal is very attractive as coating for magnetic nanopar-
ticles. Also, functionalization of the gold surface with
thiol groups, allows the linkage of functional ligands and
subsequently make the materials suitable for catalytic
and optical applications [55,56].
Calcium phosphate nanoparticles, routinely used for
in vitro transfection, have been investigated as a power-
ful non-viral gene delivery [57]. These nanoparticles
alone, or in combination with other vectors (viral or
nonviral), show good gene delivery properties especially
when incorporated in the colloidal particulate systems
[58]. Indeed, divalent metal cations, such as Ca+2, Mg+2,
Mn+2, and Ba+2 can form ionic complexes with the DNA
thus give stabilized structures. The complexes can then be
carried across cell membrane via ion channel-mediated
endocytosis. Because of low transfection efficiency and in-
ability to apply in vivo conditions, calcium phosphate can
be considered as a more efficient material compared to
other viral and non-viral vectors. These drawbacks can be
overcome by preparing ultra-low size calcium phosphate
nanoparticles entrapping DNA molecules [59,60]. Further-
more, calcium phosphate nanoparticles are very safe and
can overcome many targeting problems such as an effi-
cient endosomal escaping, rendering sufficient protec-
tion of DNA in the cytosol and providing an easy
passage of cytosolic DNA to the nucleus [59]. These
nanoparticles can be useful in gene delivery in the
treatment of bone defects due to high calcium phos-
phate content of the bone [61]. It seems that the use of
nanotubes, nanoshells, and mesoporous nanoparticles
(such as silica mesoporous nanoparticle) is a promising idea
for gene delivery because of their hollow and porous struc-
tures and facile surface fictionalization as well [62].
Recently, the application of silica nanoparticles has
been reported as a non-viral vector for efficient in vivo
gene delivery. Silica nanoparticles functionalized with
amino groups can efficiently bind to plasmid DNA and
protect it from enzymatic digestion and effect cell
transfection in vitro. It has been shown that by loading
of DNA on the modified silica nanoparticles, DNA has
been protected from degradation by DNase which can
effectively be taken up by COS-1 cells [63]. This type
of silica nanoparticles overcomes many of the limita-
tions of unmodified silica nanoparticles. Indeed thepresence of organic group on the surface of these nanopar-
ticles imparts some degree of flexibility to the otherwise
rigid silica matrix and increases the stability of them in
aqueous systems. Based on the previous investigation
results, these nanoparticles as a non-viral gene delivery
carriers have a promising future direction for effective
therapeutic manipulation of the neural stem/progeni-
tor cells as well as in vivo targeted brain therapy [12].
Functionalized dendrimer-like hybrid silica nanoparti-
cles are attractive nanocarriers for the advanced deliv-
ery of various sized drugs and genes simultaneously
because these nanoparticles have hierarchical pores,
unique structure, large surface area, and excellent
biocompability [64].
Quantum dot (QD) has been successfully applied for
in vitro and in vivo transfection. QDs are nearly spherical
semiconductor particles with core-shell structure. The
semiconducting nature and the size-dependent fluores-
cence of these nanocrystals have made them very attractive
for diagnosis of diseases. Gene-associated drugs can be
loaded within a QD core or attached to the surface of these
nanoparticles through direct conjugation or electrostatic
complexation by which QDs can protect the gene from
degradation by nucleases [65-67]. Super paramagnetic
iron oxide nanoparticles (SPIONS) are utilized as gene
delivery systems. In pulmonary gene delivery systems,
either branched biodegradable polyesters or PEG-coated
super paramagnetic iron oxide nanoparticles are promising
carriers. These nanoparticles can maintain their transfec-
tion ability at in vivo condition after nebulization [68,69].
However, there are challenges, such as the standardization
of therapy response and the stability of complex nanoparti-
cles under certain biological conditions. SPION are known
to be an excellent carrier for siRNA delivery because they
are biocompatible and target-functionalized. In spite of
hard-to-transfect cell lines, the novel method such as
magnetofection can be used for delivering of SPION with
plasmid DNA or siRNA, where these nanoparticles is sub-
jected to oscillating magnetic fields that facilitate caveolae-
mediated endocytosis of SPION and cargo nucleic acid
[70]. Due to nano-dimension size and also stability, inor-
ganic nanoparticles are being extensively used as promising
gene carriers. All of reviewed studies signify that inorganic
nanoparticles such as gold and silica possess attractive
properties such as high fictionalization ability, good bio-
compatibility, low toxicity, and potential capability of tar-
geted delivery [71]. Also, it seems that functionalized CNTs
according to their large inner volume (that allows the
loading of small biomolecules), quantum dots because
of their unique luminescent properties, Calcium phos-
phate nanoparticles due to wide availability and high
safety, and lately, SPIONs owing to their valuable mag-
netic properties are appropriate candidates as carriers
for gene transfection.
Figure 2 Schematic processes of LPD formation.
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Hybrid nanoparticles can be categorized into two
groups: liposome-polycation-DNA (LPD) nanoparticles
and multilayered nanoparticles. LPD nanoparticles can
be fabricated by spontaneous rearrangement of a lipid
shell around a polycation-DNA core (Figure 2) [72].
Indeed, they are complexes which consist of liposomes
(that are either made of cationic (LPDI) or anionic (LPDII)
lipids) and polyplexes sometimes referred to as lipopoly-
plexes. Polycations, unlike cationic polypeptides such as
poly-L-lysine, histone, and protamine can be condensing
DNA in highly compressed structures in nanometric diam-
eter. Formation of multilayered nanoparticles are carried
out through layer-by-layer (LbL) assembly of polycations
and polyanions (e.g., DNA). The properties of the self-
assembled multilayers depend on the choice of their build-
ing blocks. Using of multifunctional gene vectors improve
the loading dose of DNA cellular uptake, controlling the re-
lease of DNA and target delivery [25,73]. Some important
properties and advantages/disadvantages of non-viral vec-
tors are presented in Tables 1 and 2, respectively.Table 1 Characterizations of nanoparticulate non-viral vector
Non-viral vectors Transferring efficiency Prepara
Inorganic nanoparticles Low Easy
Polymer-based nanoparticles Low Easy
Lipid-based nanoparticles Low Difficu
Hybrid nanoparticles High EasyConclusion
Gene delivery is one of the recent attractive therapeutic
methods that involved viral and non-viral vectors. From
the stability and safety point of view, non-viral vectors
have more efficiency in gene transfection. Non-viral
vectors can be efficiently passing through biological bar-
riers compared to viral vectors. Among these vectors,
nanoparticle carriers have been successfully applied for
in vitro gene delivery and efforts continue in improving
in vivo applications. While a wide variety of organic, in-
organic, or hybrid materials are used for the production
of nanoparticles, polymeric nanoparticles have great
therapeutic application. Polymeric nanoparticles can be
produced in a wide range of sizes and varieties and can
be used in sustained and targeted gene delivery for longs in gene delivery
tion Cellular toxicity Applications References
Frequently toxic In vitro [18,48,56]
Low toxicity In vitro [25,29,31]
lt Toxic (at high dose) In vitro [20]
Low toxicity In vitro/In vivo [25,73]
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materials for gene delivery, natural biopolymers can po-
tentially avoid many of the safety concerns with viral
gene delivery due to high biocompatibility, low toxicity,
and good biodegradability. In conclusion, the utilization
of biopolymers such as proteins, polypeptides, and poly-
saccharides will be one of the potentially promising
methods for gene delivery. However, the clinical applica-
tion of gene delivery still is in its initial stage, but more
progression of it is expected in the near future.
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